- Nov 09 2016
PDS presents human phase I/IIA data demonstrating excellent safety and T-cell induction
Dr. Shepard, CMO of PDS Biotechnology, to Present PDS0101 Phase I/IIA Clinical Data at the Society for Immunotherapy of Cancer Meeting on November 11, 2016
PDS Biotechnology announced today that Dr. Robert Shepard, MD, Chief Medical Officer, will present data from PDS’s recently completed Phase I/IIA clinical trial with its lead cancer immunotherapy, PDS0101 at the 31st Annual Meeting of the Society for Immunotherapy of Cancer (SITC). PDS0101 is being developed to treat HPV-induced cancers, including Cervical, Anal and Head and Neck cancers. The meeting is being held at the Gaylord National Hotel & Convention Center in National Harbor, Maryland.